Digital Transformation in the Pharmaceutical Market Research Report 2019
Situation Overview
Introduction
APEJ Is Evolving
Technological Adoption
APEJ Countries - Readiness
China
Government Drive
Data Protection
India
Government Drive
Data Protection
Australia
Government Drive
Data Protection
South Korea
Government Drive
Data Protection
Positive Drive
Research and Development
Manufacturing
Distribution
Commercials
Supply Chain Management
Use Cases
Internet of Things
Artificial Intelligence
Blockchain
3D Printing
Patient Data Platform
Advice for the Technology Buyer
Learn More
Related Research
This IDC Perspective provides a picture of the various technological tools that can be adopted in various stages of the value chain by pharmaceutical companies as they go for digital transformation. The regional readiness for the transformational adoption has been confirmed by analyzing a set of regional countries on the government drive and data protection policy in place. Use cases were discussed to provide a better visualization of the emerging tools. As pharmaceutical leaders are busy strategizing their future, IDC's advice for technology buyers would be a good guidance."Pharmaceutical companies are facing two major challenges: first, to meet the "digital consumer" demand for faster, patient-centric, outcome-based medicines; and second, to attain these demands at reduced drug prices. The only way to tackle both challenges is to adopt digitalization or digital transformation across the value chain. This could well be achieved as pharmaceutical leaders take digital disruption as an opportunity and not as a risk," says Manoj Vallikkat, research manager, Healthcare Insights, IDC Asia/Pacific.